^{116TH CONGRESS} 2D SESSION H.R.6739

AUTHENTICATED U.S. GOVERNMENT INFORMATION

> To amend title XVIII of the Social Security Act to require coverage under Medicare PDPs and MA–PD plans, without the imposition of cost sharing or utilization management requirements, of drugs intended to treat COVID–19 during certain emergencies.

IN THE HOUSE OF REPRESENTATIVES

May 8, 2020

Mr. CASTEN of Illinois introduced the following bill; which was referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned

A BILL

- To amend title XVIII of the Social Security Act to require coverage under Medicare PDPs and MA–PD plans, without the imposition of cost sharing or utilization management requirements, of drugs intended to treat COVID– 19 during certain emergencies.
 - 1 Be it enacted by the Senate and House of Representa-
 - 2 tives of the United States of America in Congress assembled,

3 SECTION 1. SHORT TITLE.

4 This Act may be cited as the "Ensuring Seniors' Ac-

5 cess to COVID Treatments Act".

| 1 | SEC. 2. REQUIRING COVERAGE UNDER MEDICARE PDPS |
|----|---|
| 2 | AND MA-PD PLANS, WITHOUT THE IMPOSI- |
| 3 | TION OF COST SHARING OR UTILIZATION |
| 4 | MANAGEMENT REQUIREMENTS, OF DRUGS |
| 5 | INTENDED TO TREAT COVID-19 DURING CER- |
| 6 | TAIN EMERGENCIES. |
| 7 | (a) Coverage Requirement.— |
| 8 | (1) IN GENERAL.—Section $1860D-4(b)(3)$ of |
| 9 | the Social Security Act (42 U.S.C. 1395w- |
| 10 | 104(b)(3)) is amended by adding at the end the fol- |
| 11 | lowing new subparagraph: |
| 12 | "(I) REQUIRED INCLUSION OF DRUGS IN- |
| 13 | TENDED TO TREAT COVID–19.— |
| 14 | "(i) IN GENERAL.—Notwithstanding |
| 15 | any other provision of law, a PDP sponsor |
| 16 | offering a prescription drug plan shall, |
| 17 | with respect to a plan year, any portion of |
| 18 | which occurs during the period described |
| 19 | in clause (ii), be required to— |
| 20 | "(I) include in any formulary— |
| 21 | "(aa) all covered part D |
| 22 | drugs with a medically accepted |
| 23 | indication (as defined in section |
| 24 | 1860D-2(e)(4)) to treat COVID- |
| 25 | 19 that are marketed in the |
| 26 | United States; and |

3

| "(bb) all drugs authorized under section 564 or 564A of the Federal Food Drug and Cosmetic Act to treat COVID-19; and "(II) not impose any prior au- thorization or other utilization man- agement requirement with respect to such drugs described in item (aa) or (bb) of subclause (I) (other than such a requirement that limits the quantity of drugs due to safety). "(ii) PERIOD DESCRIBED.—For pur- poses of clause (i), the period described in this clause is the pariod during which there |
|--|
| Federal Food Drug and Cosmetic Act to treat COVID-19; and "(II) not impose any prior au- thorization or other utilization man- agement requirement with respect to such drugs described in item (aa) or (bb) of subclause (I) (other than such a requirement that limits the quantity of drugs due to safety). "(ii) PERIOD DESCRIBED.—For pur- poses of clause (i), the period described in |
| Act to treat COVID-19; and "(II) not impose any prior au- thorization or other utilization man- agement requirement with respect to such drugs described in item (aa) or (bb) of subclause (I) (other than such a requirement that limits the quantity of drugs due to safety). "(ii) PERIOD DESCRIBED.—For pur- poses of clause (i), the period described in |
| "(II) not impose any prior authorization or other utilization management requirement with respect to such drugs described in item (aa) or (bb) of subclause (I) (other than such a requirement that limits the quantity of drugs due to safety). "(ii) PERIOD DESCRIBED.—For purposes of clause (i), the period described in |
| thorization or other utilization man- agement requirement with respect to such drugs described in item (aa) or (bb) of subclause (I) (other than such a requirement that limits the quantity of drugs due to safety). "(ii) PERIOD DESCRIBED.—For pur- poses of clause (i), the period described in |
| agement requirement with respect to such drugs described in item (aa) or (bb) of subclause (I) (other than such a requirement that limits the quantity of drugs due to safety). "(ii) PERIOD DESCRIBED.—For pur- poses of clause (i), the period described in |
| such drugs described in item (aa) or (bb) of subclause (I) (other than such a requirement that limits the quantity of drugs due to safety). "(ii) PERIOD DESCRIBED.—For pur- poses of clause (i), the period described in |
| (bb) of subclause (I) (other than such a requirement that limits the quantity of drugs due to safety). "(ii) PERIOD DESCRIBED.—For purposes of clause (i), the period described in |
| a requirement that limits the quantity of drugs due to safety). "(ii) PERIOD DESCRIBED.—For pur- poses of clause (i), the period described in |
| of drugs due to safety). "(ii) PERIOD DESCRIBED.—For pur- poses of clause (i), the period described in |
| "(ii) PERIOD DESCRIBED.—For purposes of clause (i), the period described in |
| poses of clause (i), the period described in |
| |
| this clause is the period during which there |
| this clause is the period during which there |
| exists the public health emergency declared |
| by the Secretary pursuant to section 319 |
| of the Public Health Service Act on Janu- |
| ary 31, 2020, entitled 'Determination that |
| a Public Health Emergency Exists Nation- |
| wide as the Result of the 2019 Novel |
| Coronavirus' (including any renewal of |
| such declaration pursuant to such sec- |
| tion).". |
| (b) Elimination of Cost Sharing.— |
| |

| 1 | (1) Elimination of cost sharing for |
|----|--|
| 2 | DRUGS INTENDED TO TREAT COVID–19 UNDER |
| 3 | STANDARD AND ALTERNATIVE PRESCRIPTION DRUG |
| 4 | COVERAGE.—Section 1860D–2 of the Social Security |
| 5 | Act (42 U.S.C. 1395w–102) is amended— |
| 6 | (A) in subsection (b)— |
| 7 | (i) in paragraph (1)(A), by striking |
| 8 | "The coverage" and inserting "Subject to |
| 9 | paragraph (8), the coverage"; |
| 10 | (ii) in paragraph (2)— |
| 11 | (I) in subparagraph (A), by in- |
| 12 | serting after "Subject to subpara- |
| 13 | graphs (C) and (D)" the following: |
| 14 | "and paragraph (8)"; |
| 15 | (II) in subparagraph (C)(i), by |
| 16 | striking "paragraph (4)" and insert- |
| 17 | ing "paragraphs (4) and (8)"; and |
| 18 | (III) in subparagraph (D)(i), by |
| 19 | striking "paragraph (4)" and insert- |
| 20 | ing "paragraphs (4) and (8)"; |
| 21 | (iii) in paragraph (4)(A)(i), by strik- |
| 22 | ing "The coverage" and inserting "Subject |
| 23 | to paragraph (8), the coverage"; and |
| 24 | (iv) by adding at the end the following |
| 25 | new paragraph: |

"(8) 1 ELIMINATION OF COST-SHARING FOR 2 DRUGS INTENDED TO TREAT COVID-19.-The cov-3 erage does not impose any deductible, copayment, 4 coinsurance, or other cost-sharing requirement for 5 drugs described in section 1860D-4(b)(3)(I)(i)(I)6 with respect to a plan year, any portion of which oc-7 curs during the period during which there exists the 8 public health emergency declared by the Secretary 9 pursuant to section 319 of the Public Health Service 10 Act on January 31, 2020, entitled 'Determination 11 that a Public Health Emergency Exists Nationwide 12 as the Result of the 2019 Novel Coronavirus' (in-13 cluding any renewal of such declaration pursuant to 14 such section)."; and 15 (B) in subsection (c), by adding at the end 16 the following new paragraph: 17 "(4) SAME ELIMINATION OF COST-SHARING FOR 18 DRUGS INTENDED TO TREAT COVID-19.-The cov-19 erage is in accordance with subsection (b)(8).". 20 (2)ELIMINATION OF COST SHARING FOR 21 DRUGS INTENDED TO TREAT COVID-19 DISPENSED 22 TO INDIVIDUALS WHO ARE SUBSIDY ELIGIBLE INDI-23 VIDUALS.—Section 1860D–14(a) of the Social Secu-24 rity Act (42 U.S.C. 1395w–114(a)) is amended—

25 (A) in paragraph (1)—

| | 0 |
|----|---|
| 1 | (i) in subparagraph (D)— |
| 2 | (I) in clause (ii), by striking "In |
| 3 | the case of' and inserting "Subject to |
| 4 | subparagraph (F), in the case of"; |
| 5 | and |
| 6 | (II) in clause (iii), by striking |
| 7 | "In the case of" and inserting "Sub- |
| 8 | ject to subparagraph (F), in the case |
| 9 | of"; and |
| 10 | (ii) by adding at the end the following |
| 11 | new subparagraph: |
| 12 | "(F) Elimination of cost-sharing for |
| 13 | drugs intended to treat covid-19.—Cov- |
| 14 | erage that is in accordance with section |
| 15 | 1860D–2(b)(8)."; and |
| 16 | (B) in paragraph (2)— |
| 17 | (i) in subparagraph (B), by striking |
| 18 | "A reduction" and inserting "Subject to |
| 19 | subparagraph (F), a reduction''; |
| 20 | (ii) in subparagraph (D), by striking |
| 21 | "The substitution" and inserting "Subject |
| 22 | to subparagraph (F), the substitution"; |
| 23 | (iii) in subparagraph (E), by inserting |
| 24 | after "Subject to" the following: "subpara- |
| 25 | graph (F) and"; and |
| | |

| 1 | (iv) by adding at the end the following |
|----|---|
| 2 | new subparagraph: |
| 3 | "(F) Elimination of cost-sharing for |
| 4 | DRUGS INTENDED TO TREAT COVID-19.—Cov- |
| 5 | erage that is in accordance with section |
| 6 | 1860D–2(b)(8).". |
| 7 | (c) IMPLEMENTATION.—Notwithstanding any other |
| 8 | provision of law, the Secretary of Health and Human |
| 9 | Services may implement the amendments made by this |
| 10 | section by program instruction or otherwise. |

 \bigcirc